Approximately 10–20% of patients with non-small-cell lung carcinoma (NSCLC) in Western countries and 40–50% in East Asia have tumors harboring somatic activating mutations in EGFR [2,3]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.